Related Experiment Video

Updated: Aug 8, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease

A Anvari1, E Schuster, M Gottsauner-Wolf

  • 1Department of Cardiology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Thrombosis Research
|July 18, 2001
PubMed

Insights

The plasminogen activator inhibitor type I (PAI-I) 4G/4G genotype is linked to a higher risk of sudden cardiac death (SCD) in coronary artery disease (CAD) patients. This finding highlights PAI-I as a potential biomarker for SCD risk in this population.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Thrombosis Research

Background:

  • The plasminogen activator inhibitor type I (PAI-I) gene polymorphism (4G/5G) is implicated in coronary artery disease (CAD).
  • The specific association between PAI-I polymorphism and sudden cardiac death (SCD) in CAD patients remains under-investigated.

Purpose of the Study:

  • To investigate the role of PAI-I gene polymorphism in patients with CAD and a history of SCD.
  • To test the hypothesis that the 4G/4G genotype contributes to myocardial ischemia and SCD in CAD patients.

Main Methods:

  • Genotyping of PAI-I 4G/5G polymorphism and measurement of plasma PAI-I antigen levels.
  • Comparison between 97 CAD patients with SCD history (defibrillator group) and 113 CAD patients without SCD history (control group).

Main Results:

  • The SCD group exhibited a higher prevalence of 4G/4G homozygotes (44% vs. 24%) and elevated PAI-I levels compared to controls.
  • Carriers of the 4G allele showed a significantly increased risk for SCD (OR 1.9), with the 4G/4G genotype conferring the highest risk (OR 3.6).

Conclusions:

  • The PAI-I 4G/4G genotype is significantly associated with an increased risk of SCD in patients diagnosed with CAD.
  • PAI-I polymorphism may serve as a valuable genetic marker for identifying CAD patients at higher risk for sudden cardiac death.
Abstract

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...